Modulators of cystic fibrosis transmembrane conductance regulator

US11426407B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Mark Miller · San Diego, US
• Corey Anderson · San Diego, US
• Vijayalaksmi Arumugam · San Marcos, US
• Brian Bear · Oceanside, US
• Hayley Binch · Harwell, GB
• Jeremy J. Clemens · San Diego, US
• Thomas Cleveland · San Diego, US
• Erica Conroy · Columbus, US
• Timothy Richard Coon · Carlsbad, US
• Bryan A. Frieman · Village of La Jolla, US
• Peter Diederik Jan Grootenhuis · San Diego, US
• Raymond Stanley Gross · Poway, US
• Sara Sabina Hadida-Ruah
• Haripada Khatuya · San Diego, US
• Pramod Joshi · San Diego, US
• Paul Krenitsky · San Diego, US
• Chun-Chieh Lin · San Diego, US
• Gulin Erdogan Marelius · San Diego, US
• Vito Melillo · Escondido, US
• Jason McCartney · Encinitas, US
• Georgia McGaughey Nicholls · Winchester, US
• Fabrice Pierre · Cugnaux, FR
• Alina Silina · San Diego, US
• Andreas P. Termin · Encinitas, US
• Johnny Uy · San Diego, US
• Jinglan Zhou · San Diego, US

Key dates

• Filing date: Mar 31, 2020
• Grant date: Aug 30, 2022
• Expiry date: Mar 31, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.